Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer

Urology

Volumn 48, Issue 5, 1996, Pages 703-710

  Senga, Yasuhiro ^a   Kimura, Go ^a   Hattori, Tomotaka ^a   Yoshida, Kazuhiro ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

ARTICLE; BLADDER CANCER; BLOOD LEVEL; CANCER STAGING; CONTROLLED STUDY; CYSTITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TRANSURETHRAL RESECTION; TUMOR VOLUME; URINE LEVEL; UROLITHIASIS;

ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KERATINS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; URINE;

EID: 0030297746     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00253-1     Document Type: Article

References (19)

1. 1. Steinert PM, and Roop DR: Molecular and cellular biology of intermediate filaments. Annu Rev Biochem 57: 593-625, 1988.
2. 2. Moll R, Franke WW, and Schiller DL: The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31: 11-24, 1982.
3. 3. Franke WW, Jahn L, Knapp AC: Cytokeratins and desmosomal proteins in certain epithelioid and non-epithelial cells, in Osborn M, Weber K (Eds): Cytoskeletal Proteins in Tumor Diagnosis. Cold Spring Harbor, NY, Cold Spring Harbor Laboratories, 1989, pp 151-172.
4. 4. Debus E, Moll R, Franke WW, Weber K, and Osborn M: Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies. Am J Pathol 114: 121-130, 1984.
5. 5. Sundstrom BE, Natrath WBJ, and Stigbrand T: Diversity in immunoreactivity of tumor derived cytokeratin monoclonal antibodies. J Histochem Cytochem 37: 1848-1854, 1989.
6. 6. Bros JL, Rot MK, Ostendorp T, Huysmans A, Wagenaar SS, Wiersmavan-Tilburg AJ, Vooijs GP, and Ramaekers FC: Immunohistochemical detection of human lung cancer heterogeneity using antibodies to epithelial, neuronal and neuroendocrine antigens. Cancer Res 47: 3225-3234, 1987.
7. 7. Bros JL, Ramaekers FC, Rot MK, Ostendorp T, Huysmans A, van Muijen GN, Wagenaar SS, and Vooijs GP: Cytokeratin in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res 48: 3221-3229, 1988.
8. 8. Bodenmuller H, Banauch D, Ofenloch B, Jaworek D, and Dessauer A: Technical evaluation of a new automated tumor marker assay: the Enzyme-Test CYFRA 21-1, in Klapdor R (Ed): Tumor Associated Antigens, Oncogenes, Receptors, Cytokines in Tumor Diagnosis and Therapy at the Beginning of the 1990s. München, Zuckschwerdt Verlag, 1992, pp 137-138.
9. 9. Bodenmuller H, Banauch D, Ofenloch-Hanle B, Jaworek D, and Dessauer A: Technical and clinical evaluation of a new assay for NSCLC, the Enzyme-Test CYFRA 21-1. Proc AACR 33: 203, 1992.
10. 10. Karsten U, Papsdorf P, Roloff G, Stolley P, and Abel H: Monoclonal anti-cytokeratin antibody from a hybridoma clone generated by electrofusion. Eur J Cancer Clin Oncol 21: 733-740, 1985.
11. 11. Petra S, Ute H, Heinz B, Dorothea N, Ludger SP, Hendrik D, Werner M, and Ahmad FM: CYFRA 21-1. A new marker in lung cancer. Cancer 72: 707-713, 1993.
12. 12. Yasuo S, and Satoshi K: Clinical evaluation of soluble cytokeratin 19 fragments in sera - A new marker for non small cell lung carcinoma. Kokyuu 13: 60-67, 1994.
13. 13. Hsu S, Raine L, and Fanger H: The use of avidinbiotin-peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and labeled antibody (PAP) procedure. J Histochem Cytochem 29: 577-580, 1981.
14. 14. Edward AR, Kristin LCB, and James HR: Discrimination of cell types in primary transitional cell carcinoma by monoclonal anti-cytokeratin antibodies. Pathology 58: 304-311, 1990.
15. 15. Edward AR, Heatfield BM, Trump BF, and Resau JH: Correlation of cytokeratin patterns with histopathology during neoplastic progression in rat urinary bladder. Pathobiology 58: 15-27, 1990.
16. 16. Edward AR, Cottrell JR, and Resau JH: Correlation of DNA ploidy levels with altered cytokeratin patterns in rat bladder tumors. Pathobiology 59: 62-68, 1991.
17. 17. Helmy H, Seddek MN, Basta MT, Shaaban A, el-Baz ME, el-Masry SE, al-Hilaly ES, and Ghoneim MA: Cytokeratin shedding in urine as a biological marker for bladder cancer: monoclonal antibody-based evaluation. Br J Urol 68: 248-253, 1991.
18. 18. Frable WJ, Paxon L, and Barksdale JA: Current practice of urinary bladder cytology. Cancer Res 37: 2800-2805, 1987.
19. 19. Stieber P, Dienemann H, Hasholzner U, Fabricius PG, Schambeck C, Weinzierl M, Poley S, Samtleben W, Hofmann K, Meier W, et al: Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int J Biol Markers 9: 82-88, 1994.